Hospital
Willits Hospital INC.
Willits Hospital INC. was paid $15.00M by Medicaid between Jan 2018 and Nov 2024, across 172 billing codes. Its largest line is 99283, emergency room visit (moderate) — 26% of everything it billed.
33Billing provider infoWILLITS HOSPITAL INC.
WILLITS, CA 95490
WILLITS, CA 95490
33aNPI1356339543assigned 10/11/2005
33bProvider typeCritical Access Hospital
28Total paid$15.00M
24GClaims322,702
24DCodes billed172
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Critical Access Hospital providers in California
Rank by total paid#5 of 30
Median peer was paid$3.14M
This provider vs. median4.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official PRIDGEN, PARKER controls 18+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,779 | $1.79M | |
| 2019 | 45,282 | $1.72M | |
| 2020 | 38,566 | $1.53M | |
| 2021 | 45,634 | $2.28M | |
| 2022 | 52,455 | $2.85M | |
| 2023 | 54,955 | $2.76M | |
| 2024incomplete | 44,031 | $2.07M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 26% | 33,569 | 28,487 | $3.88M |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 19% | 25,585 | 22,556 | $2.81M |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 5.3% | 2,820 | 2,770 | $793K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 3.8% | 5,653 | 5,057 | $564K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 2.9% | 1,826 | 958 | $433K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 2.8% | 9,318 | 1,916 | $424K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 2.4% | 1,106 | 1,051 | $366K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | 2.0% | 2,424 | 2,408 | $302K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.9% | 4,040 | 3,554 | $288K |
| 70450 | Computed tomography, head or brain; without contrast material | 1.7% | 1,433 | 1,377 | $252K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 1.5% | 4,689 | 4,341 | $221K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 1.4% | 1,718 | 1,402 | $213K |
160 more codes
| 96361 | Intravenous infusion, hydration; each additional hour | 1.2% | 4,673 | $175K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 6,736 | $168K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | 1.1% | 1,595 | $168K |
| 80053 | Comprehensive metabolic panel | 1.0% | 20,007 | $153K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,335 | $141K |
| 97750 | <1% | 1,495 | $137K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 2,694 | $137K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 1,737 | $136K |
| 99201 | <1% | 682 | $133K | |
| 97139 | <1% | 3,846 | $131K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 23,576 | $131K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 1,246 | $129K |
| J3490 | Unclassified drugs | <1% | 13,763 | $129K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 1,291 | $118K |
| 87507 | <1% | 246 | $97K | |
| 73721 | Magnetic resonance imaging, any joint of lower extremity; without contrast material | <1% | 186 | $89K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 2,217 | $85K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 1,275 | $80K |
| 71045 | Radiologic examination, chest; single view | <1% | 6,267 | $78K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 157 | $75K |
| 73610 | <1% | 2,128 | $73K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 6,096 | $72K |
| 76830 | Ultrasound, transvaginal | <1% | 642 | $72K |
| 93010 | Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | <1% | 4,661 | $71K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 649 | $71K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 136 | $70K |
| 73630 | <1% | 1,886 | $63K | |
| 73562 | <1% | 1,902 | $61K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 1,238 | $60K |
| 76700 | Ultrasound, abdominal, real time with image documentation; complete | <1% | 459 | $54K |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | <1% | 1,189 | $52K |
| 73130 | <1% | 1,267 | $49K | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 5,132 | $49K |
| 73030 | <1% | 1,166 | $47K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,833 | $46K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 2,027 | $46K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,806 | $45K |
| 73110 | <1% | 1,227 | $44K | |
| 87631 | <1% | 512 | $42K | |
| J2704 | Injection, propofol, 10 mg | <1% | 1,568 | $41K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 995 | $38K |
| 80061 | Lipid panel | <1% | 3,694 | $33K |
| 81001 | <1% | 9,675 | $32K | |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,655 | $29K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,962 | $29K |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,508 | $28K |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 348 | $28K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 4,726 | $28K |
| 84484 | <1% | 2,576 | $23K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,309 | $22K |
| 83880 | <1% | 877 | $21K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,584 | $20K |
| 83690 | <1% | 3,980 | $20K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 780 | $19K |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 1,579 | $19K |
| 87186 | <1% | 2,180 | $19K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 300 | $18K |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 1,990 | $17K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 2,824 | $17K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 1,036 | $16K |
| 99070 | <1% | 1,430 | $16K | |
| 80306 | <1% | 766 | $15K | |
| 83605 | <1% | 1,725 | $15K | |
| 73221 | <1% | 25 | $15K | |
| 87040 | <1% | 1,469 | $14K | |
| 72141 | <1% | 27 | $14K | |
| 87077 | <1% | 2,127 | $13K | |
| 86140 | <1% | 3,417 | $13K | |
| 84439 | <1% | 1,832 | $11K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 24 | $10K |
| 81025 | <1% | 2,757 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,450 | $9K |
| 83735 | <1% | 1,917 | $9K | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,163 | $9K |
| 82728 | <1% | 949 | $9K | |
| 85610 | <1% | 2,714 | $8K | |
| 86803 | <1% | 752 | $7K | |
| 93971 | <1% | 45 | $7K | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 700 | $7K |
| 72110 | <1% | 92 | $6K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 907 | $6K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 27 | $6K |
| 87081 | <1% | 1,173 | $6K | |
| 90715 | <1% | 86 | $6K | |
| 73502 | <1% | 107 | $5K | |
| 87486 | <1% | 136 | $5K | |
| 87581 | <1% | 135 | $5K | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 519 | $5K |
| 85730 | <1% | 1,090 | $5K | |
| 83540 | <1% | 1,054 | $5K | |
| 87070 | <1% | 717 | $4K | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 598 | $4K |
| 85652 | <1% | 2,266 | $4K | |
| 72100 | <1% | 106 | $4K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 117 | $4K |
| 87510 | <1% | 256 | $4K | |
| 87480 | <1% | 256 | $4K | |
| 85379 | <1% | 440 | $3K | |
| 83550 | <1% | 586 | $3K | |
| 82746 | <1% | 300 | $3K | |
| 20985 | <1% | 25 | $3K | |
| 82607 | <1% | 267 | $3K | |
| 97803 | <1% | 40 | $2K | |
| 94664 | <1% | 89 | $2K | |
| 86592 | <1% | 823 | $2K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 14 | $2K |
| J2060 | Injection, lorazepam, 2 mg | <1% | 318 | $2K |
| 73080 | <1% | 41 | $2K | |
| 82962 | <1% | 786 | $2K | |
| 82948 | <1% | 860 | $2K | |
| 76770 | <1% | 27 | $2K | |
| 0450 | Emergency room services | <1% | 37 | $2K |
| 76536 | <1% | 13 | $2K | |
| 80143 | <1% | 90 | $2K | |
| 80179 | <1% | 89 | $1K | |
| 73140 | <1% | 42 | $1K | |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 27 | $1K |
| 80076 | <1% | 240 | $1K | |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 230 | $1K |
| 76000 | <1% | 207 | $1K | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 46 | $1K |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 65 | $911.03 |
| 84481 | <1% | 71 | $821.25 | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 43 | $699.30 |
| 87640 | <1% | 28 | $698.60 | |
| 85027 | <1% | 142 | $649.71 | |
| 73090 | <1% | 27 | $639.54 | |
| 72040 | <1% | 12 | $617.98 | |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 12 | $607.03 |
| A9579 | Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml | <1% | 28 | $598.00 |
| 84145 | <1% | 34 | $582.21 | |
| 83721 | <1% | 83 | $539.56 | |
| 86901 | <1% | 207 | $411.57 | |
| 86900 | <1% | 208 | $402.54 | |
| 12001 | <1% | 14 | $397.60 | |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | <1% | 29 | $387.03 |
| 87641 | <1% | 14 | $345.80 | |
| S0119 | Ondansetron, oral, 4 mg (for circumstances falling under the medicare statute, use hcpcs q code) | <1% | 338 | $323.13 |
| J0134 | Injection, acetaminophen (fresenius kabi), not therapeutically equivalent to j0131, 10 mg | <1% | 18 | $262.28 |
| 87340 | <1% | 31 | $211.70 | |
| 86850 | <1% | 87 | $179.92 | |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 13 | $175.04 |
| 84550 | <1% | 52 | $152.35 | |
| 86038 | <1% | 13 | $138.19 | |
| 86141 | <1% | 12 | $134.28 | |
| 73560 | <1% | 27 | $132.87 | |
| 86039 | <1% | 13 | $131.04 | |
| J3370 | Injection, vancomycin hcl, 500 mg | <1% | 14 | $129.43 |
| 82570 | <1% | 31 | $127.49 | |
| 82043 | <1% | 25 | $114.76 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 12 | $98.40 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 14 | $84.36 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 15 | $77.70 |
| 74018 | <1% | 13 | $77.28 | |
| S0028 | Injection, famotidine, 20 mg | <1% | 14 | $74.90 |
| 82550 | <1% | 12 | $65.98 | |
| 87205 | <1% | 12 | $33.24 | |
| 85007 | <1% | 16 | $32.55 | |
| J8540 | Dexamethasone, oral, 0.25 mg | <1% | 16 | $1.28 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | <1% | 12 | $0.24 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialPRIDGEN, PARKER (PRESIDENT)
| Provider | Location | Paid |
|---|---|---|
| Adventist Health Clearlake Hospital INC. | Clearlake, CA | $78.57M |
| Adventist Health Clearlake Hospital INC. | Paradise, CA | $74.62M |
| Adventist Health Clearlake Hospital INC. | Clearlake, CA | $35.14M |
| Ukiah Adventist Hospital | Ukiah, CA | $14.62M |
| Adventist Health Mendocino Coast | Fort Bragg, CA | $7.74M |
| Willits Hospital INC | Willits, CA | $6.04M |
| Adventist Health Clearlake Hospital INC. | Corning, CA | $5.66M |
| Adventist Health Clearlake Hospital, INC | Lower Lake, CA | $4.14M |
| Adventist Health Clearlake Hospital INC | Lakeport, CA | $3.34M |
| Adventist Health Clearlake Hospital, INC | Lucerne, CA | $2.88M |
| Adventist Health Clearlake Hospital INC. | Middletown, CA | $2.40M |
| Adventist Health Clearlake Hospital INC | Clearlake, CA | $2.25M |
| Adventist Health Clearlake Hospital INC | Hidden Valley Lake, CA | $2.03M |
| Adventist Health Clearlake Hospital INC. | Kelseyville, CA | $1.63M |
| Ukiah Adventist Hospital | Ukiah, CA | $1.40M |
| Adventist Health Clearlake Hospital, INC | Lakeport, CA | $1.05M |
| Ukiah Adventist Hospital | Fort Bragg, CA | $844K |
| Willits Hospital INC. | Willits, CA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.